Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Jane M. Grant-Kels MD, FAAD Advisory Board

Ashish C. Bhatia MD, FAAD Associate Editor

Sarah L. Chamlin MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · February 22, 2024

Estimated Spending on Beremagene Geperpavec for the Treatment of Patients With Dystrophic Epidermolysis Bullosa

JAMA Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

JAMA Dermatology

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

JAMA Dermatol 2024 Jan 31;[EPub Ahead of Print], AJN Raymakers, AS Kesselheim, A Mostaghimi, WB Feldman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Estimated Spending on Beremagene Geperpavec for the Treatment of Patients With Dystrophic Epidermolysis Bullosa

Additional Info

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

Further Reading

Final Note From the Dermatology Editors

Outcomes of Treatment With 5-Fluorouracil 5% Cream in Patients With Squamous Cell Carcinoma In Situ

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Recently Updated